Teladoc Health (TDOC) Stock Overview
Provides virtual healthcare services worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
TDOC Community Fair Values
Create NarrativeSee what 89 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Teladoc Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.28 |
| 52 Week High | US$9.77 |
| 52 Week Low | US$4.40 |
| Beta | 2.1 |
| 1 Month Change | 32.01% |
| 3 Month Change | 81.96% |
| 1 Year Change | 11.54% |
| 3 Year Change | -62.54% |
| 5 Year Change | -93.68% |
| Change since IPO | -67.44% |
Recent News & Updates
Narrative Update • Jun 15
TDOC: Walmart Distribution And BetterHelp Access Will Shape Balanced Future Outlook
Narrative Update: Teladoc Health Analyst Target Revision Analysts have nudged Teladoc Health's fair value estimate higher, with the implied price target moving from about $7.12 to roughly $7.40 as they factor in updated assumptions on revenue growth, profit margins, and the potential impact of distribution partnerships such as the recently announced Walmart Better Care Services rollout. Analyst Commentary Recent research on Teladoc Health reflects a mixed but active debate, with several firms updating their price targets and views on the company following sector-wide pressure in MedTech and the rollout of new partnerships such as the Walmart Better Care Services arrangement.
Narrative Update • Jun 01
TDOC: Persistent Margin Strains Will Outweigh Walmart Partnership And Guidance Lift
Analysts have nudged Teladoc Health's implied price outlook higher, with a modestly lower discount rate and P/E assumptions and slightly firmer margin expectations helping to support updated targets that now cluster around the $8 to $11 range highlighted in recent research. Analyst Commentary Research commentary on Teladoc Health has been mixed, with some large firms highlighting potential upside and others flagging execution and valuation risks.Narrative Update • May 11
TDOC: Slower Revenue Outlook And Margin Pressure Will Limit Platform Reset
Teladoc Health's updated analyst price target edges higher to $5.00 as analysts balance recent upward and downward target revisions, along with views on slower revenue growth, slightly stronger margins, and modestly lower assumed future P/E and discount rates. Analyst Commentary Recent Street research on Teladoc Health has been mixed, with several firms trimming price targets while a few others highlight potential upside tied to virtual therapy and integrated care.Recent updates
Narrative Update • Jun 15
TDOC: Walmart Distribution And BetterHelp Access Will Shape Balanced Future Outlook
Narrative Update: Teladoc Health Analyst Target Revision Analysts have nudged Teladoc Health's fair value estimate higher, with the implied price target moving from about $7.12 to roughly $7.40 as they factor in updated assumptions on revenue growth, profit margins, and the potential impact of distribution partnerships such as the recently announced Walmart Better Care Services rollout. Analyst Commentary Recent research on Teladoc Health reflects a mixed but active debate, with several firms updating their price targets and views on the company following sector-wide pressure in MedTech and the rollout of new partnerships such as the Walmart Better Care Services arrangement.Narrative Update • Jun 01
TDOC: Persistent Margin Strains Will Outweigh Walmart Partnership And Guidance Lift
Analysts have nudged Teladoc Health's implied price outlook higher, with a modestly lower discount rate and P/E assumptions and slightly firmer margin expectations helping to support updated targets that now cluster around the $8 to $11 range highlighted in recent research. Analyst Commentary Research commentary on Teladoc Health has been mixed, with some large firms highlighting potential upside and others flagging execution and valuation risks.Narrative Update • May 11
TDOC: Slower Revenue Outlook And Margin Pressure Will Limit Platform Reset
Teladoc Health's updated analyst price target edges higher to $5.00 as analysts balance recent upward and downward target revisions, along with views on slower revenue growth, slightly stronger margins, and modestly lower assumed future P/E and discount rates. Analyst Commentary Recent Street research on Teladoc Health has been mixed, with several firms trimming price targets while a few others highlight potential upside tied to virtual therapy and integrated care.
Narrative Update • Apr 24
TDOC: BetterHelp Insurance Shift Will Drive Future Margin Recovery Potential
Teladoc Health's analyst price target has been adjusted from about $12 to around $10.50, as analysts factor in updated growth, margin and valuation assumptions that reflect mixed views on the BetterHelp transition, Integrated Care trends and recent sector readthroughs. Analyst Commentary Recent Street research around Teladoc Health clusters around two themes: a reset in expectations after guidance and renewed interest in the BetterHelp and Integrated Care assets.Seeking Alpha • Apr 11
Teladoc Health: Improving Fundamentals Support A Turnaround Story
Summary Teladoc Health is transitioning from a cyclical D2C model to a higher-margin, data-driven B2B platform, supporting a Buy rating at low multiples. TDOC's BetterHelp segment is pivoting to insurance reimbursement, aiming for $75–90M in 2026 insurance revenue, reducing churn and acquisition costs. Integrated Care leverages PulseAI and proprietary datasets to deliver predictive, high-ROI services to employers and health plans, supporting premium pricing and margin expansion. Improving free cash flow, reduced debt, activist pressure, and potential strategic actions position TDOC for re-rating as operational momentum builds. Read the full article on Seeking AlphaNarrative Update • Apr 09
TDOC: Virtual Therapy And Care Platform Reset Will Shape Balanced Outlook
Teladoc Health's updated analyst price target reflects only a modest shift. Analysts point to mixed revisions across the Street as they weigh concerns about revenue declines and profit margins against views that the current valuation and virtual therapy assets may be undervalued.Narrative Update • Mar 26
TDOC: Future Upside Hinges On BetterHelp Insurance Shift Execution
Teladoc Health's updated analyst price target now centers around $7, down from about $9, as analysts factor in tempered revenue growth and margin expectations, along with a higher discount rate, partially balanced by views that the current valuation and focused plans for BetterHelp and Integrated Care still support some P/E multiple resilience. Analyst Commentary Recent research shows a wide spread in views on Teladoc Health, with price targets clustering around the mid single digits but reaching as high as US$11.Narrative Update • Mar 12
TDOC: Virtual Therapy Assets And 24 7 Care Evolution Will Shape Balanced Outlook
Our Teladoc Health fair value estimate has been reduced from $6.50 to $5.00 as we align with a Street backdrop in which several firms have cut targets into the $5 to $7 range, while others highlight what they see as compelling valuation, underappreciated virtual therapy assets, and a possible exit path. Analyst Commentary Street research on Teladoc Health has turned mixed, with a cluster of lower price targets sitting alongside a handful of upgrades that point to what some see as an attractive entry point at current levels.Narrative Update • Feb 26
TDOC: Expanded 24/7 Care Services Will Support Confidence Despite Lower Street Expectations
Narrative Update on Teladoc Health Our updated view reflects a reduced analyst price target for Teladoc Health to $9, with analysts pointing to ongoing sector-wide pressures in health tech, a modestly higher discount rate, and slightly adjusted expectations for revenue growth, profit margins, and future P/E multiples as key drivers of the change. Analyst Commentary Recent Street research on Teladoc Health points to a series of price target cuts that cluster around the US$9 level, reinforcing a cautious tone on the stock.Narrative Update • Feb 10
TDOC: Future Care Platform Expansion Will Drive Confidence Despite Lower Street Expectations
Narrative Update Analysts have trimmed their blended price target on Teladoc Health by about $1 to reflect recent cuts from firms such as Goldman Sachs, Citi, BofA, and BMO. They cite ongoing challenges for health tech in 2025, along with cautious optimism for 2026 and early signs that Teladoc's revenue revival efforts and BetterHelp adoption could support a steadier outlook over time.Analysis Article • Feb 04
Teladoc Health, Inc.'s (NYSE:TDOC) 28% Dip In Price Shows Sentiment Is Matching Revenues
Unfortunately for some shareholders, the Teladoc Health, Inc. ( NYSE:TDOC ) share price has dived 28% in the last...Narrative Update • Jan 27
TDOC: Cautious Outlook Balances Telehealth Execution Risks With Emerging Care Platform Opportunities
Narrative Update Analysts have trimmed their Teladoc Health fair value estimate by $0.50 to $6.50, citing updated expectations for revenue growth, profit margins, discount rates, and future P/E multiples following recent Street price target reductions to a range of $8 to $9. Analyst Commentary Street research over recent months has tilted cautious on Teladoc Health, with several firms trimming price targets into the high single digits and emphasizing execution and growth risks.Analysis Article • Nov 23
Teladoc Health, Inc. (NYSE:TDOC) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Teladoc Health, Inc. ( NYSE:TDOC ) shares have had a horrible month, losing 26% after a relatively good period...Analysis Article • Aug 27
Teladoc Health, Inc. (NYSE:TDOC) Shares Could Be 49% Below Their Intrinsic Value Estimate
Key Insights Teladoc Health's estimated fair value is US$15.45 based on 2 Stage Free Cash Flow to Equity Teladoc Health...Analysis Article • Jul 31
The Teladoc Health, Inc. (NYSE:TDOC) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
There's been a notable change in appetite for Teladoc Health, Inc. ( NYSE:TDOC ) shares in the week since its...Analysis Article • Jun 18
Teladoc Health, Inc.'s (NYSE:TDOC) Low P/S No Reason For Excitement
Teladoc Health, Inc.'s ( NYSE:TDOC ) price-to-sales (or "P/S") ratio of 0.5x might make it look like a strong buy right...Seeking Alpha • Apr 16
Teladoc: Back In The Doldrums After Another Tough Year (Rating Downgrade)
Summary Teladoc Health, Inc.'s stock has declined significantly, from a high of $14 per share in February to $7 per share, with ongoing financial struggles and underperformance in key segments. The company reported a net loss of $1 billion in 2024, with declining revenues in its BetterHelp segment and minimal growth in Integrated Care. Despite efforts to cut costs and new initiatives like the Catapult Health acquisition and a partnership with Eli Lilly, Teladoc's value proposition remains unclear. Given the persistent losses, low utilization rates, and lack of clear growth prospects, I am downgrading TDOC stock from "Hold" to "Sell" ahead of Q1 earnings. Read the full article on Seeking AlphaSeeking Alpha • Mar 26
Teladoc's Meltdown May Not Be Over Yet - Minimal Growth Opportunities
Summary Teladoc's mixed FQ4'24 performance and underwhelming FY2025 guidance continue to point to its mixed growth profile, despite the new management and recent acquisition. This is worsened by the ongoing user acquisition issues, intensifying competition in the primary/preventive care segment, and ongoing uncertainties observed in the healthcare market. Despite the still positive Free Cash Flow generation and richer balance sheet, it remains to be seen when TDOC's growth may materialize. Combined with the higher short interest volume on a YoY basis and ongoing insider selling, it is uncertain when we may see a floor materialize. Read the full article on Seeking Alpha
New Narrative • Mar 23
Integration Of Catapult Health And Global Partnerships Will Shape Future Success
Strategic focus on customer growth and tech innovation enhances service offerings, boosting visit volumes and revenue through visit-oriented arrangements.Seeking Alpha • Feb 27
Teladoc Q4 Earnings: A Waiting Game For Investors (Rating Downgrade)
Summary Teladoc Health, Inc.'s disappointing guidance and lack of revenue growth have led me to adopt a neutral stance on TDOC stock despite its cheap valuation at 7x forward free cash flow. My investment strategy focuses on businesses with strong balance sheets and the potential for significant free cash flow growth, but Teladoc's fundamentals don't align with this narrative. Teladoc's manageable debt and plans to retire convertible debt improve its financial footing, but I need to see revenue momentum before considering it investable again. The healthcare market's shift towards visit-based payment models poses additional risks for Teladoc, making it prudent to wait and reassess its growth potential. Read the full article on Seeking AlphaSeeking Alpha • Feb 19
Teladoc Health: Amazon To The Rescue, Potentially
Summary Teladoc Health's collaboration with Amazon Health has driven a stock rally, but the partnership's impact remains uncertain without Amazon's active promotion. The telehealth company faces challenges with higher customer acquisition costs in the BetterHelp segment, impacting growth expectations. Investors should watch upcoming Q4 results for insights on the Amazon Health collaboration's early performance and future guidance. Despite the recent rally, TDOC stock remains relatively cheap, trading at ~7x EBITDA estimates with a market cap of $2.5 billion. Read the full article on Seeking AlphaAnalysis Article • Feb 08
Teladoc Health, Inc. (NYSE:TDOC) Surges 32% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, Teladoc Health, Inc. ( NYSE:TDOC ) shares have been powering on, with a gain of 32% in...Analysis Article • Jan 27
Is Teladoc Health (NYSE:TDOC) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Jan 10
Teladoc: Minimal Growth Left As More Healthcare Players Leave/Diversify
Summary Teladoc's decelerating performance growth metrics and moderating profit margins continue to imply that the worst may not be over yet, as more deep pocketed players leave the unprofitable telehealth space. TDOC has also failed to reinvent its telehealth offerings, one currently observed with AMWL through military/government healthcare and HIMS with personalized D2C health offerings. The new management team has already highlighted their ongoing challenges, attributed to the high medical cost trends and pressure on their current/prospective customers. It remains to be seen when we may see TDOC's growth headwinds bottom and growth materialize, as similarly observed in the discounted stock valuations and lowered forward estimates. Combined with the growing short interest volume and the potential equity dilution from the Livongo 2025 notes, there remains great uncertainties surrounding TDOC's future prospects. Read the full article on Seeking AlphaSeeking Alpha • Dec 20
Teladoc: Attractive Valuation, But The Narrative Stalls
Summary I find Teladoc appealing for contrarian investors, trading at just 6x forward operating cash flow, 60% below the sector median, and industry peers. Nonetheless, I believe the company lacks a compelling, forward-looking narrative to drive a turnaround in investor sentiment, despite its low valuation. I’m concerned that cost-cutting efforts, like reducing marketing and R&D, won't generate sustainable growth or shift investor sentiment. I believe Teladoc's new AI virtual sitter could face regulatory obstacles and potentially limited demand, raising doubts about its viability as a growth driver. I prefer to stay on the sidelines and pay a premium once the share price breaks $14–$15, signaling stronger investor confidence and a clearer path to a turnaround. Read the full article on Seeking AlphaSeeking Alpha • Nov 27
Teladoc: Maybe This Goose Isn't Cooked Yet (Rating Upgrade)
Summary Teladoc Health, Inc.'s telehealth model struggles with low utilization despite its potential, leading to consistent operating losses and a declining average revenue per member. New CEO Chuck Divita aims to revitalize Teladoc by enhancing value propositions, cutting costs, and potentially selling or restructuring the BetterHelp segment. Teladoc's survival hinges on cost-cutting, maintaining integrated care clients, and resolving BetterHelp's profitability issues, with a cautious outlook for 2025. Upgrading to “hold” from “sell” as Teladoc shows potential for a turnaround, despite ongoing challenges and a tough path to profitability. Read the full article on Seeking AlphaAnalysis Article • Nov 26
Teladoc Health, Inc. (NYSE:TDOC) Surges 40% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, Teladoc Health, Inc. ( NYSE:TDOC ) shares have been powering on, with a gain of 40% in...Analysis Article • Nov 02
Teladoc Health, Inc. (NYSE:TDOC) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Investors in Teladoc Health, Inc. ( NYSE:TDOC ) had a good week, as its shares rose 7.5% to close at US$9.21 following...Analysis Article • Oct 23
Is Teladoc Health (NYSE:TDOC) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Oct 13
Teladoc: Double-Digit FCF Yield, Possible BetterHelp Transition
Summary Teladoc's valuation could be reaching a bottom at the current LTM FCF yield of 20%. BetterHelp which currently accounts for 41% of revenue, is a key component of Teladoc growth potential. Investors should wait to see if the new CEO makes a strategic swift especially for BetterHelp which could be more profitable as a B2B offering. Read the full article on Seeking AlphaAnalysis Article • Sep 18
Teladoc Health, Inc. (NYSE:TDOC) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Those holding Teladoc Health, Inc. ( NYSE:TDOC ) shares would be relieved that the share price has rebounded 28% in the...Seeking Alpha • Sep 15
Teladoc Health: Some Negative Things, But One Aspect That Makes Me Feel Positive
Summary Teladoc's stock fell ~97% from its peak, but recent changes, including a new CEO, present a high-risk, high-reward opportunity. Positive year-over-year trends in integrated care members and chronic care enrollment, but effective monetization of these members remains a challenge. However, Teladoc's strong FCF and cheap valuation, trading at 4-5 times FCF, make it a potential turnaround candidate. Read the full article on Seeking AlphaSeeking Alpha • Sep 04
Teladoc: Prospects Are Ready For Better Health
Summary I believe Teladoc Health's current challenges have already been priced into its stock. I'm watching closely for signs of stabilization in Teladoc's revenue growth rates. I'm neutral on Teladoc for now but see potential at a 10x to 12x forward free cash flow multiple. If Teladoc's fundamentals improve, I might upgrade my rating to a clear buy. Read the full article on Seeking AlphaSeeking Alpha • Aug 01
Teladoc Post Q2 Earnings: Stick A Fork In This Stock - It's Nearly Done (For)
Summary Teladoc Health, Inc. stock has plummeted >95% since its peak in early 2021, with the downtrend near constant. Losses are usually exacerbated by quarterly earnings, and Q2 earnings, announced yesterday, were no exception. Teladoc's new CEO withdrew all guidance for 2024, signaling potential challenges ahead, especially with the BetterHelp segment facing high customer acquisition costs and churn. The other division, Integrated Care, earned just $1.36 per member every year, according to my understanding. In short, while logically Teladoc's value proposition makes sense, the company finds itself in a very difficult position and may be doomed to failure — like many of its rivals. Read the full article on Seeking AlphaSeeking Alpha • Jul 22
Teladoc's Vital Signs: Why 5x FCF Means Stable Health (Rating Upgrade)
Summary I no longer believe it makes sense to sustain a bearish outlook on Teladoc, as its current valuation already reflects many negative aspects. At approximately 5x next year's free cash flow, Teladoc presents a better risk-reward profile than it has in quite some time. Teladoc’s balance sheet, while not flawless, is manageable and can be improved with focused efforts. Read the full article on Seeking AlphaAnalysis Article • Jul 17
Teladoc Health, Inc.'s (NYSE:TDOC) Revenues Are Not Doing Enough For Some Investors
You may think that with a price-to-sales (or "P/S") ratio of 0.7x Teladoc Health, Inc. ( NYSE:TDOC ) is a stock worth...Seeking Alpha • Jul 01
Teladoc Health: Weight Loss Management Could Help
Summary Teladoc Health, Inc. faces an internal crisis with stock at all-time lows and a new CEO. The company has massive opportunities in weight loss management, but the focus appears more on telesales and digital advertising over product innovation. Teladoc Health stock trades at a cheap valuation with potential for multiple expansion, if the new CEO drives product innovation. Read the full article on Seeking AlphaShareholder Returns
| TDOC | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 0.9% | -1.2% | 0.6% |
| 1Y | 11.5% | -37.0% | 19.5% |
Return vs Industry: TDOC exceeded the US Healthcare Services industry which returned -37% over the past year.
Return vs Market: TDOC underperformed the US Market which returned 19.5% over the past year.
Price Volatility
| TDOC volatility | |
|---|---|
| TDOC Average Weekly Movement | 8.1% |
| Healthcare Services Industry Average Movement | 9.8% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TDOC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TDOC's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 5,124 | Chuck Divita | www.teladochealth.com |
Teladoc Health, Inc. provides virtual healthcare services worldwide. It operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical services, specialty medical, chronic condition management, and mental health services, as well as technologies and enterprise telehealth solutions for hospitals and health systems.
Teladoc Health, Inc. Fundamentals Summary
| TDOC fundamental statistics | |
|---|---|
| Market cap | US$1.66b |
| Earnings (TTM) | -US$171.15m |
| Revenue (TTM) | US$2.51b |
0.7x
P/S Ratio-9.8x
P/E RatioIs TDOC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TDOC income statement (TTM) | |
|---|---|
| Revenue | US$2.51b |
| Cost of Revenue | US$772.29m |
| Gross Profit | US$1.74b |
| Other Expenses | US$1.91b |
| Earnings | -US$171.15m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | 69.29% |
| Net Profit Margin | -6.81% |
| Debt/Equity Ratio | 74.5% |
How did TDOC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/10 21:39 |
| End of Day Share Price | 2026/07/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Teladoc Health, Inc. is covered by 34 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Peter Warendorf | Barclays |
| Ravi Misra | Berenberg |